Omadacycline is in phase III clinical trials for the treatment of complicated acute bacterial skin and skin structure infections (ABSSSI). It was granted qualified infectious disease product designation by FDA for the treatment of ABSSSI in 2013. And it received Fast Track designation for skin and soft tissue infection on November 06, 2015.
The compound was originally developed by Paratek, then licensed to Merck Sharp & Dohme in 2006.
|CAS No.||389139-89-3 (Omadacycline);|
|Chemical Name||2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-|
|Omadacycline （Free Acid/Base）Parameters：|
|*：Calculated by ACD/Labs software V11.02.|